FUTURE PLANS

See "Business — Our Strategies" in this document for a detailed description of our future plans.

USE OF [REDACTED]

Assuming that the [**REDACTED**] is not exercised, after deducting the [**REDACTED**] and other estimated [**REDACTED**] expenses payable by us in connection with the [**REDACTED**], and assuming an [**REDACTED**] of HK$[**REDACTED**] per H Share (being the mid-point of the indicative [**REDACTED**] of HK$[**REDACTED**] and HK$[**REDACTED**]), we estimate that we will receive net [**REDACTED**] of approximately HK$[**REDACTED**] million from the [**REDACTED**]. We intend to use the [**REDACTED**] from the [**REDACTED**] for the purposes and in the amounts set forth below:

- Approximately [**REDACTED**]% of the net [**REDACTED**], or HK$[**REDACTED**] million, is expected to be used for the nationwide expansion of our major business segments.

  - approximately [**REDACTED**]% of the net [**REDACTED**], or HK$[**REDACTED**] million, is expected to be used for continuously developing our warehousing facilities nationwide and optimizing our national warehouse network. We have an extensive warehouse network in Sichuan Province and have built our new warehouse in Tianjin. We intend to upgrade the automated equipment in our existing warehousing facilities to further enhance the accuracy and efficiency of inventory selection and categorization, which, in turn, helps us to reduce costs. Moreover, we plan to set up three new warehouses via leasing at key logistics hubs across regions with significant primary healthcare potential, such as Central China, Southern China and Northwestern China, to meet the needs for expanding our pharmaceutical supply network on a nationwide scale. We plan to adopt advanced inventory equipment and systems in our new warehousing facilities. Furthermore, to effectively operate our existing and new warehouses, we aim to increase the number of our warehouse management personnel to meet the needs for expanding our pharmaceutical supply network. We also intend to further enhance the digitalization and intelligence of our WMS and logistics systems to support the development of our pharmaceutical supply network.

  - approximately [**REDACTED**]% of the net [**REDACTED**], or HK$[**REDACTED**] million, is expected to be allocated to further strengthening our nationwide business development and customer coverage capabilities across all of our business segments. We plan to recruit additional senior business development personnel and establish regional business development hubs in new regions, thereby expanding our local sales and customer service team with core in-house members, enhancing our brand presence and improving customer coverage within new regions. Furthermore, we plan to intensify marketing and promotional activities in markets where we already have a presence to further increase our market penetration. Our enhanced business development capabilities not only echo our strategy to enhance the scale of our testing and diagnostic solutions and integrated diagnostic and treatment solutions as well as to expand our pharmaceutical direct supply network, but will also serve to market our new products and services with heightened level of digital intelligence to the market, diversifying our empowerment capabilities.

  - approximately [**REDACTED**]% of the net [**REDACTED**], or HK$[**REDACTED**] million, is expected to be allocated to further developing and optimizing our services and solutions. For the pharmaceutical direct supply and distribution services, we plan to recruit additional personnel with medical backgrounds and leverage our professional expertise to identify and address unmet medication needs in the primary healthcare market. We also intend to expand our team of senior procurement managers to strengthen strategic partnerships with reliable upstream pharmaceutical manufacturers. Furthermore, we intend to increase our investment in product selection research to enhance efficiency in screening new products. These collectively allow us to enrich our SKU portfolio for our pharmaceutical direct supply and distribution services. In addition, we plan to allocate resources to expand our POCT equipment capabilities to broaden our testing and diagnostic solutions by selecting and procuring more types of useful POCT equipment. Moreover, we intend to strengthen our customer service team by increasing headcount and providing more on-boarding and on-the-job staff training in relation to customer service, medical knowledge and management capabilities to enhance overall service capabilities.

- Approximately [**REDACTED**]% of the net [**REDACTED**], or HK$[**REDACTED**] million, is expected to be used for developing a robust R&D environment to empower the primary healthcare market. We plan to enhance our existing R&D capabilities by attracting information technology professionals, such as IT engineers, product managers and R&D project managers, to expand our R&D team for the development and enhancement of our APPs targeting the primary healthcare industry in China. We plan to recruit more middle to senior level IT professionals with extensive R&D experience in the AI technology market to enhance our technological and AI capabilities. We also intend to increase investment in IT hardware and software, through purchasing IT infrastructure components such as servers, software products and external computing power services, among others, to establish our own data center. This will serve as the foundation for enhancing our digitalization and intelligence to support the future development of our services and solutions. In addition, we plan to continue the development and enhancement of our AI capabilities, including AI-assisted diagnosis as well as AI-empowered medical knowledge base, patient management and clinic management. We intend to adopt a combination of in-house development and collaborative R&D to continuously upgrade or launch APPs, mini-programs and other digital tools tailored for the primary healthcare industry in China. We believe that this is in line with our strategy of deepening our empowerment to primary healthcare and building a digitally intelligent ecosystem for the participants of the primary healthcare industry.

- Approximately [**REDACTED**]% of the net [**REDACTED**], or HK$[**REDACTED**] million, is expected to be used for potential strategic investment and merger and acquisition opportunities. We intend to selectively pursue external growth opportunities, which may include: (i) product or service providers targeting the primary healthcare industry in China, such as suppliers of popular pharmaceuticals and other healthcare products as well as POCT equipment, Software-as-a-Service ("**SaaS**") providers and AI application providers; and (ii) companies that similarly focus on the primary healthcare industry in China and possess channel advantages in certain regional markets.

- Approximately [**REDACTED**]% of the net [**REDACTED**], or HK$[**REDACTED**] million, is expected to be used for working capital and for general corporate purposes.

To the extent that the net [**REDACTED**] from the [**REDACTED**] are either more or less than expected, we will adjust our allocation of the net [**REDACTED**] for the above purposes on a pro rata basis.

To the extent that the net [**REDACTED**] of the [**REDACTED**] are not immediately used for the above purposes or if we are unable to effect any part of our future development plans as intended, we will only deposit the net [**REDACTED**] into short-term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions (as defined under the Securities and Futures Ordinance or the applicable laws and regulations in other jurisdictions). In such an event, we will comply with the appropriate disclosure requirements under the Listing Rules.